Riluzole sublingual - Biohaven Pharmaceutical

Drug Profile

Riluzole sublingual - Biohaven Pharmaceutical

Alternative Names: BHV-0223

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; Yale University
  • Class Benzothiazoles; Neuroprotectants; Small molecules; Thiazoles
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Spinocerebellar degeneration
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Social phobia
  • Phase I Amyotrophic lateral sclerosis; Generalised anxiety disorder; Mood disorders

Most Recent Events

  • 09 May 2018 Biohaven announces intention to submit NDA to the US FDA for Amyotrophic lateral sclerosis in the third quarter of 2018
  • 09 May 2018 Biohaven initiates Expanded access programme for Amyotrophic lateral sclerosis in USA (NCT03537807)
  • 02 Feb 2018 Phase-I clinical trials in Amyotrophic lateral sclerosis in USA (Sublingual) (NCT03520517)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top